Jonathan Basil Fitzgerald
20Patents
8h-index
28Co-inventors
71Inventor score
Filing activity: Aug 17, 2009 → May 25, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9492442B2 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Human Necessities | 16 | Active |
| US9339497B2 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Human Necessities | 16 | Active |
| US8476409B2 | Bispecific anti-IGF-1R and anti-ErbB3 antibodies | Chemistry; Metallurgy | 14 | Active |
| US9717724B2 | Methods for treating pancreatic cancer using combination therapies | Human Necessities | 12 | Active |
| US9452162B2 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Human Necessities | 11 | Active |
| US10478428B2 | Combination therapy for cancer treatment | Human Necessities | 11 | Active |
| US9364473B2 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Human Necessities | 11 | Active |
| US9895365B2 | Combination therapy for cancer treatment | Human Necessities | 10 | Active |
| US10980795B2 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Human Necessities | 7 | Active |
| US8623592B2 | Methods and systems for predicting response of cells to a therapeutic agent | Chemistry; Metallurgy | 6 | Active |
| US11071726B2 | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | Human Necessities | 5 | Active |
| US11318131B2 | Nanoliposomal irinotecan for use in treating small cell lung cancer | Human Necessities | 3 | Active |
| US11344552B2 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | Human Necessities | 3 | Active |
| US11369597B2 | Methods for treating pancreatic cancer using combination therapies | Human Necessities | 3 | Active |
| US11844795B2 | Combination therapy for cancer treatment | Human Necessities | 2 | Active |
| US9556274B2 | Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies | Chemistry; Metallurgy | 2 | Active |
| US9527914B2 | Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies | Chemistry; Metallurgy | 1 | Active |
| US9938346B2 | Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies | Chemistry; Metallurgy | 0 | Active |
| US10744130B2 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | General | 0 | Revoked |
| US12364691B2 | Methods for treating pancreatic cancer using combination therapies | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.